We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00295165
Recruitment Status : Terminated
First Posted : February 23, 2006
Last Update Posted : December 4, 2013
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )

Brief Summary:
The purpose of this study is to evaluate if Leukine can induce clinical response or remission in patients with Crohn's disease.

Condition or disease Intervention/treatment Phase
Crohn Disease Drug: Sargramostim (Leukine) Drug: Placebo Phase 3

Detailed Description:
On 29 May 2009, Bayer began transitioning the sponsorship of this trial to Genzyme. NOTE: This study was originally posted by sponsor Berlex, Inc. Berlex, Inc. was renamed to Bayer HealthCare, Inc.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Induction Study to Assess the Efficacy and Safety of 6µg Sargramostim (Leukine) Administered Subcutaneously Once Daily for 8 Weeks in Patients With Active Crohn's Disease
Study Start Date : January 2006
Actual Primary Completion Date : October 2006
Actual Study Completion Date : October 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Crohn's Disease

Arm Intervention/treatment
Experimental: Arm 1 Drug: Sargramostim (Leukine)
Sargramostim 6 mcg/kg subcutaneously once daily
Other Name: BAY86-5326

Placebo Comparator: Arm 2 Drug: Placebo
Placebo subcutaneously once daily

Primary Outcome Measures :
  1. To induce clinical remission and/or clinical response following 8 weeks of treatment [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. To assess the safety profile of sargramostim (including development of antibodies against sargramostim) [ Time Frame: During study treatment ]
  2. To assess quality of life (QoL) [ Time Frame: During study treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Written informed consent
  2. Male or female, age >/= 18 years
  3. Confirmed diagnosis of Crohn's disease (endoscopic or radiological evaluation) at least 4 months prior to receiving the first dose of study drug
  4. Moderately to severely active Crohn's disease at time of screening (i.e., CDAI greater than or equal to 220 and less than or equal to 475 points)
  5. If under treatment for Crohn's disease, medication must be stable for at least 4 weeks prior to receiving the first dose of study drug. The following therapies are allowed:

    • Oral therapy with salicylates (mesalamine, sulfasalazine, olsalazine, or balsalazide) for Crohn's disease
    • Antibiotics or probiotics for Crohn's disease
    • Topical rectal therapy with mesalamine
  6. Females of child-bearing potential:

    Negative pregnancy test within 72 hours prior to receiving the first dose of study drug

  7. Sexually-active males and females of child-bearing potential:

    Agreement to use adequate method of contraception throughout the study

  8. Ability to self-inject study drug or availability of a designee who can do so

Exclusion Criteria:

  1. Pregnancy or breast-feeding
  2. Colostomy or ileostomy
  3. Immediate need for gastrointestinal (GI) surgery for active GI bleeding, peritonitis, intestinal obstruction, or intra-abdominal or perianal abscess requiring surgical drainage
  4. GI surgery within 6 months prior to receiving the first dose of study drug
  5. Symptoms of bowel obstruction or confirmed evidence of a clinically-significant stricture within the last 6 months that has not been surgically corrected
  6. Positive stool test results for any of the following:


    • Salmonella spec.
    • Shigella spec.
    • Campylobacter spec.

    Bacterial toxin:

    • Clostridium difficile

    Ova and parasites:

    • Amoeba spec.
    • Giardia spec.
    • Cryptosporidium spec.
  7. Any of the following laboratory abnormalities:

    • Serum creatinine >/= 2.0 mg/dL
    • Alkaline phosphatase (AP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin >/=; 2 x the upper limit of normal
    • Hemoglobin (Hgb) < 8.0 g/dL
    • Absolute neutrophil count (ANC) </= 1,000 cells/µL or > cells 20,000/µL
  8. Planned in-patient hospitalization during the study
  9. Presence or history of cancer of any type (except treated basal cell carcinoma) or definite dysplasia of the colon within the last 5 years
  10. Use of any of the following medications during the specified period of time prior to receiving the first dose of study drug:

    At any time:

    • Recombinant human GM CSF (sargramostim or molgramostim)
    • Granulocyte colony-stimulating factor (G CSF; filgrastim or pegfilgrastim)
    • Natalizumab 8 weeks: or 5 half-lives (whichever is longer)
    • Licensed/registered and/or experimental anti-tumor necrosis factor (TNF) therapy such as infliximab or adalimumab 4 weeks:
    • 6-mercaptopurine
    • Azathioprine
    • Cyclophosphamide
    • Methotrexate
    • Mycophenolate mofetil
    • Tacrolimus
    • Cyclosporine
    • Thalidomide
    • Glucocorticoids, including budesonide and prednisone, or local glucocorticoid therapy for Crohn's disease
    • Any other immunosuppressive drugs
  11. Use of any investigational drug within 4 weeks or 5 half-lives (whichever is longer) prior to receiving the first dose of study drug
  12. Use of nutritional therapy (parenteral nutrition or enteral nutrition with elemental or semi-elemental diets) within 4 weeks prior to receiving the first dose of study drug. If the physician judges that nutritional supplementation is needed, enteral nutritional supplements will be allowed for patients who have been receiving a stable regimen for at least 4 weeks prior to receiving the first dose of study drug and that is intended to continue through the 8 week treatment period.
  13. History of allergy to yeast products or to sargramostim or to any other excipient of the study drug formulation
  14. Active drug or alcohol abuse
  15. Clinically important co-morbid conditions unrelated to Crohn's disease as determined by the investigator
  16. Previous randomization into this study, or into any other study of the sponsor's sargramostim development program

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00295165

Show Show 111 study locations
Sponsors and Collaborators
Genzyme, a Sanofi Company
Layout table for investigator information
Study Director: Medical Monitor Genzyme, a Sanofi Company
Layout table for additonal information
Responsible Party: Genzyme, a Sanofi Company
ClinicalTrials.gov Identifier: NCT00295165    
Obsolete Identifiers: NCT00295321
Other Study ID Numbers: 310187
First Posted: February 23, 2006    Key Record Dates
Last Update Posted: December 4, 2013
Last Verified: December 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Immunologic Factors
Physiological Effects of Drugs